RxSight boasted about booming demand for its cataract surgery system. But, in the end, the company took the scalpel to investors wallets. After investors got blindsided by plummeting demand and a slashed revenue guidance, shareholders dumped their stock. RxSight's stock price crashed by almost 40%. Now, investors are suing.

RxSight manufacturers a surgical kit which it says helps people with cataracts. From late 2024 to early 2025, RxSight kept up a story of surging demand and great revenue. In early 2025 it even issued an eye-popping revenue guidance. But it was all smoke, no substance.

Investors learned the truth in July after the company admitted demand was crashing out. The Company slashed its revenue guidance. Furious investors dumped their shares, sending the stock into freefall.

Now, more investors are joining the lawsuit.